TORONTO, ONTARIO–(Marketwired – Dec. 1, 2015) – Arch Biopartners Inc., (Arch or the Company) (TSX VENTURE:ACH)(OTCBB:FOIFF), today announced it has successfully completed quality control and pre-clinical validation of a synthesis of MetaMx™ which was produced by a third party chemistry manufacturer in the U.S.
2015
Arch Biopartners Receives Orphan Drug Designation from FDA for AB569
TORONTO, ONTARIO–(Marketwired – Nov. 13, 2015) – Arch Biopartners Inc., (Arch or the Company) (TSX VENTURE:ACH)(OTCBB:FOIFF) a portfolio based biotechnology company focused on developing innovative technologies that make a significant clinical impact on patients, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for AB569 in the treatment of Pseudomonas aeruginosa (P. aeruginosa) pulmonary infections in patients with cystic fibrosis.
Arch Biopartners Retains Virtus Advisory to Provide Investor Relations Services
TORONTO, ONTARIO–(Marketwired – Oct. 21, 2015) – Arch Biopartners Inc (Arch) or (the Company) (TSX VENTURE:ACH)(OTCBB:FOIFF), today announced that it has retained Virtus Advisory Group Inc. (“Virtus”), to develop and implement a strategic investor relations program, which includes enhancing the Company’s exposure among industry stakeholders and investors across Canada.
Arch Biopartners: AB569 Successfully Completes Pre-Clinical Validation Studies
TORONTO, CANADA–(Marketwired – Sept. 17, 2015) – Arch Biopartners Inc (Arch) or (the Company) (TSX VENTURE:ACH)(OTCBB:FOIFF) announced AB569, the Company’s drug candidate for treating pulmonary Pseudomonas aeruginosa (P. aeruginosa) infections, has successfully completed pre-clinical in vivo and in vitro validation studies.
Arch Biopartners Announces Issuance of U.S. Patent for Brain Tumor Targeting Peptides
TORONTO, CANADA–(Marketwired – Aug. 5, 2015) – Arch Biopartners Inc (Arch) or (the Company) (TSX VENTURE:ACH)(OTCBB:FOIFF) announced today the U.S. Patent and Trademark Office (USPTO) has issued U.S. Patent 9,095,541 titled, “Brain Tumor Targeting Peptides”, further protecting MetaMx™, the Company’s peptide based technology which targets brain tumour initiating cells (BTICs) and invasive glioma cells (IGCs).
Arch Biopartners Announces Issuance of a Second U.S. Patent for Peptide Solid Surface Interface
TORONTO, ONTARIO–(Marketwired – Aug. 4, 2015) – Arch Biopartners Inc (Arch) or (the Company) (TSX VENTURE:ACH)(OTCBB:FOIFF) announced today the U.S. Patent and Trademark Office (USPTO) has issued U.S. Patent 9,096,775 titled, “Surface Coated Structures and Methods”.
Arch Scientists Use ‘BORG’ Peptides to Improve Biocompatibilty of Polysulfone for Use in Dialysis
TORONTO, ONTARIO–(Marketwired – July 23, 2015) – Arch Biopartners Inc (Arch) or (the Company)(TSX VENTURE:ACH) (OTCBB:FOIFF) announced today that Arch scientists have published details of their new technology and its potential applications in the area of dialysis.
Dr. Sheila Singh, MD PhD. Joins Arch Biopartners as Medical and Clincial Advisor
TORONTO, ONTARIO–(Marketwired – June 8, 2015) – Arch Biopartners Inc (Arch) or (the Company) (TSX VENTURE:ACH)(OTCBB:FOIFF), today announced Dr. Sheila Singh will join the Company as a medical and clinical advisor to the development of MetaMx™, the Company’s brain tumor initiating cell (BTIC) targeting technology.
Arch Biopartners 2015 AGM Results and Technology Status Update
TORONTO, CANADA–(Marketwired – April 1, 2015) – Arch Biopartners Inc (“Arch”) or the “Company”)(TSX VENTURE:ACH) and (OTCBB:FOIFF) announced results from its Annual General Meeting of Shareholders held in Toronto on March 30, 2015.
Arch Biopartners Identifies Candidate Drug to Treat Psuedomonas Respiratory Infections
TORONTO, ONTARIO–(Marketwired – March 18, 2015) – Arch Biopartners Inc (“Arch”) or the “Company”)(TSX VENTURE:ACH) and (OTCBB:FOIFF) announced today it has identified a new candidate drug to treat Pseudomonas aeruginosa respiratory infections.